CNSP - CIK 0001729427
The table below shows CNS Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.65M | -$3.24M | -$3.19M | -$4.82M | -$3.08M | -$3.31M |
| Capital expenditure | $6.18K | $0.00 | - | - | $0.00 | $3.67K |
| Investing cash flow | -$6.18K | $0.00 | - | - | $0.00 | -$3.67K |
| Dividends paid | - | - | - | - | - |
CNS Pharmaceuticals, Inc. reported operating cash flow of -$13.81M for fiscal year 2025. That is up 19.3% from -$17.11M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$716.38K (FY 2018) to -$13.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $404.66K | $9.83M | $3.46M | -$120.28K | $10.51M | $347.43K |